Abacavir/lamivudine/zidovudine - GSK
Alternative Names: Abacavir/zidovudine/lamivudine; Lamivudine/abacavir/zidovudine; Lamivudine/zidovudine/abacavir; Trizivir; Zidovudine/abacavir/lamivudine; Zidovudine/lamivudine/abacavirLatest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiretrovirals; Azides; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 30 Jan 2019 Chemical structure information added
- 18 Dec 2013 First generic equivalent launched in the US for HIV-1 infections (alone or in combination with other antiretrovirals)
- 10 Dec 2013 First generic equivalent approved in US for HIV-1 infections (alone or in combination with other antiretrovirals)